A detailed history of Lindbrook Capital, LLC transactions in Cerus Corp stock. As of the latest transaction made, Lindbrook Capital, LLC holds 266 shares of CERS stock, worth $465. This represents 0.0% of its overall portfolio holdings.

Number of Shares
266
Previous 714 62.75%
Holding current value
$465
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$1.62 - $2.04 $725 - $913
-448 Reduced 62.75%
266 $0
Q1 2024

Apr 25, 2024

BUY
$1.66 - $2.42 $1,185 - $1,727
714 New
714 $1,000
Q2 2023

Jul 28, 2023

BUY
$1.79 - $2.9 $171 - $278
96 Added 112.94%
181 $0
Q1 2023

Apr 26, 2023

SELL
$2.65 - $3.81 $771 - $1,108
-291 Reduced 77.39%
85 $0
Q4 2022

Jan 24, 2023

BUY
$3.38 - $4.22 $943 - $1,177
279 Added 287.63%
376 $0
Q3 2022

Nov 10, 2022

BUY
$3.43 - $5.83 $332 - $565
97 New
97 $0
Q2 2022

Aug 01, 2022

BUY
$4.41 - $5.69 $0 - $0
0 New
0 $0

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $310M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.